An ACTH-(4–9) analogue, Org 2766, improves recovery from acrylamide neuropathy in rats
Org 2766 is one of a series of melanocortis (ACTH and related peptides) that exert trophic influences on the central and peripheral nervous system of the rat. We used acrylamide neuropathy in rats as an experimental model of peripheral neuropathies of the dying-back type in order to assess the poten...
Gespeichert in:
| Veröffentlicht in: | European journal of pharmacology 1990-09, Vol.186 (2), p.181-187 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 187 |
|---|---|
| container_issue | 2 |
| container_start_page | 181 |
| container_title | European journal of pharmacology |
| container_volume | 186 |
| creator | Sporel-Özakat, R.Emine Edwards, Philippa M. Van der Hoop, Roland Gerritsen Gispen, Willem H. |
| description | Org 2766 is one of a series of melanocortis (ACTH and related peptides) that exert trophic influences on the central and peripheral nervous system of the rat. We used acrylamide neuropathy in rats as an experimental model of peripheral neuropathies of the dying-back type in order to assess the potential therapeutic efficacy of Org 2766 in this type of nerve damage. The peptide reversed the delayed persistent deficit in sensory conduction velocity without preventing the initial loss of motor coordination. The recovery of apparently normal coordination was unaffected by the peptide, but resistance to a second toxic challenge suggested that recovery was more complete in the peptide-treated rats. The finding that Org 2766 improved the quality of the repair following acrylamide neuropathy, together with previous studies showing beneficial effects in neuropathies caused by cisplatin or diabetes and after mechanical trauma, strongly suggests that Org 2766 may be beneficial in the treatment of various conditions in which the nervous system has sustained damage. |
| doi_str_mv | 10.1016/0014-2999(90)90432-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_15870610</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0014299990904326</els_id><sourcerecordid>15870610</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-637b08bf1998408f06d2cc893448eecd37b498aec542a746cfd7be6ab0c0d1113</originalsourceid><addsrcrecordid>eNp9kMtqGzEUhkVoSB2nb5CCNi0OZNKjGY1G2hSMyQ0C3rjQndBozqQqc3GlmYB3eYe8YZ4kcmySrrI6i__7zzl8hJwyuGDAxA8AxpNUKTVTcKaAZ2kiDsiEyUIlULD0E5m8IZ_JcQh_ASBXaX5EjpgSGeP5hPyed3S-WN0kM_78-KTOqOlM09-PeE6X_p6mhRDn1LVr3z9goB5tnH5Da9-31Fi_aUzrKqQdjr5fm-HPhrqOejOEE3JYmybgl_2ckl9Xl6vFTXK3vL5dzO8Sy5kcEpEVJciyZkpJDrIGUaXWSpVxLhFtFWOupEGb89QUXNi6KkoUpgQLFWMsm5Lvu73xxX8jhkG3LlhsGtNhPwbNclmAYBBBvgOt70PwWOu1d63xG81Ab4XqrS29taUV6FehWsTa1_3-sWyxei_tDMb82z43wZqm9qazLvyHZfF4seV-7jiMMh4ceh2sw85i5aLVQVe9-_iRF3NQkFM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15870610</pqid></control><display><type>article</type><title>An ACTH-(4–9) analogue, Org 2766, improves recovery from acrylamide neuropathy in rats</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Sporel-Özakat, R.Emine ; Edwards, Philippa M. ; Van der Hoop, Roland Gerritsen ; Gispen, Willem H.</creator><creatorcontrib>Sporel-Özakat, R.Emine ; Edwards, Philippa M. ; Van der Hoop, Roland Gerritsen ; Gispen, Willem H.</creatorcontrib><description>Org 2766 is one of a series of melanocortis (ACTH and related peptides) that exert trophic influences on the central and peripheral nervous system of the rat. We used acrylamide neuropathy in rats as an experimental model of peripheral neuropathies of the dying-back type in order to assess the potential therapeutic efficacy of Org 2766 in this type of nerve damage. The peptide reversed the delayed persistent deficit in sensory conduction velocity without preventing the initial loss of motor coordination. The recovery of apparently normal coordination was unaffected by the peptide, but resistance to a second toxic challenge suggested that recovery was more complete in the peptide-treated rats. The finding that Org 2766 improved the quality of the repair following acrylamide neuropathy, together with previous studies showing beneficial effects in neuropathies caused by cisplatin or diabetes and after mechanical trauma, strongly suggests that Org 2766 may be beneficial in the treatment of various conditions in which the nervous system has sustained damage.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/0014-2999(90)90432-6</identifier><identifier>PMID: 1963145</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Acrylamide ; Acrylamides ; Adrenocorticotropic Hormone - analogs & derivatives ; Adrenocorticotropic Hormone - therapeutic use ; Animals ; Anticonvulsants - therapeutic use ; Biological and medical sciences ; Electrophysiology ; Female ; Medical sciences ; Melanocortins ; Miscellaneous ; Motor Neurons - drug effects ; Motor Neurons - metabolism ; Nervous System Diseases - chemically induced ; Nervous System Diseases - drug therapy ; Neuropathy (peripheral) ; Neuropharmacology ; Peptide Fragments - therapeutic use ; Pharmacology. Drug treatments ; Postural Balance - drug effects ; Psychomotor Performance - drug effects ; Rats ; Rats, Inbred Strains ; Synaptic Transmission - drug effects</subject><ispartof>European journal of pharmacology, 1990-09, Vol.186 (2), p.181-187</ispartof><rights>1990</rights><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-637b08bf1998408f06d2cc893448eecd37b498aec542a746cfd7be6ab0c0d1113</citedby><cites>FETCH-LOGICAL-c418t-637b08bf1998408f06d2cc893448eecd37b498aec542a746cfd7be6ab0c0d1113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0014299990904326$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19361075$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1963145$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sporel-Özakat, R.Emine</creatorcontrib><creatorcontrib>Edwards, Philippa M.</creatorcontrib><creatorcontrib>Van der Hoop, Roland Gerritsen</creatorcontrib><creatorcontrib>Gispen, Willem H.</creatorcontrib><title>An ACTH-(4–9) analogue, Org 2766, improves recovery from acrylamide neuropathy in rats</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Org 2766 is one of a series of melanocortis (ACTH and related peptides) that exert trophic influences on the central and peripheral nervous system of the rat. We used acrylamide neuropathy in rats as an experimental model of peripheral neuropathies of the dying-back type in order to assess the potential therapeutic efficacy of Org 2766 in this type of nerve damage. The peptide reversed the delayed persistent deficit in sensory conduction velocity without preventing the initial loss of motor coordination. The recovery of apparently normal coordination was unaffected by the peptide, but resistance to a second toxic challenge suggested that recovery was more complete in the peptide-treated rats. The finding that Org 2766 improved the quality of the repair following acrylamide neuropathy, together with previous studies showing beneficial effects in neuropathies caused by cisplatin or diabetes and after mechanical trauma, strongly suggests that Org 2766 may be beneficial in the treatment of various conditions in which the nervous system has sustained damage.</description><subject>Acrylamide</subject><subject>Acrylamides</subject><subject>Adrenocorticotropic Hormone - analogs & derivatives</subject><subject>Adrenocorticotropic Hormone - therapeutic use</subject><subject>Animals</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Electrophysiology</subject><subject>Female</subject><subject>Medical sciences</subject><subject>Melanocortins</subject><subject>Miscellaneous</subject><subject>Motor Neurons - drug effects</subject><subject>Motor Neurons - metabolism</subject><subject>Nervous System Diseases - chemically induced</subject><subject>Nervous System Diseases - drug therapy</subject><subject>Neuropathy (peripheral)</subject><subject>Neuropharmacology</subject><subject>Peptide Fragments - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Postural Balance - drug effects</subject><subject>Psychomotor Performance - drug effects</subject><subject>Rats</subject><subject>Rats, Inbred Strains</subject><subject>Synaptic Transmission - drug effects</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtqGzEUhkVoSB2nb5CCNi0OZNKjGY1G2hSMyQ0C3rjQndBozqQqc3GlmYB3eYe8YZ4kcmySrrI6i__7zzl8hJwyuGDAxA8AxpNUKTVTcKaAZ2kiDsiEyUIlULD0E5m8IZ_JcQh_ASBXaX5EjpgSGeP5hPyed3S-WN0kM_78-KTOqOlM09-PeE6X_p6mhRDn1LVr3z9goB5tnH5Da9-31Fi_aUzrKqQdjr5fm-HPhrqOejOEE3JYmybgl_2ckl9Xl6vFTXK3vL5dzO8Sy5kcEpEVJciyZkpJDrIGUaXWSpVxLhFtFWOupEGb89QUXNi6KkoUpgQLFWMsm5Lvu73xxX8jhkG3LlhsGtNhPwbNclmAYBBBvgOt70PwWOu1d63xG81Ab4XqrS29taUV6FehWsTa1_3-sWyxei_tDMb82z43wZqm9qazLvyHZfF4seV-7jiMMh4ceh2sw85i5aLVQVe9-_iRF3NQkFM</recordid><startdate>19900921</startdate><enddate>19900921</enddate><creator>Sporel-Özakat, R.Emine</creator><creator>Edwards, Philippa M.</creator><creator>Van der Hoop, Roland Gerritsen</creator><creator>Gispen, Willem H.</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>19900921</creationdate><title>An ACTH-(4–9) analogue, Org 2766, improves recovery from acrylamide neuropathy in rats</title><author>Sporel-Özakat, R.Emine ; Edwards, Philippa M. ; Van der Hoop, Roland Gerritsen ; Gispen, Willem H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-637b08bf1998408f06d2cc893448eecd37b498aec542a746cfd7be6ab0c0d1113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Acrylamide</topic><topic>Acrylamides</topic><topic>Adrenocorticotropic Hormone - analogs & derivatives</topic><topic>Adrenocorticotropic Hormone - therapeutic use</topic><topic>Animals</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Electrophysiology</topic><topic>Female</topic><topic>Medical sciences</topic><topic>Melanocortins</topic><topic>Miscellaneous</topic><topic>Motor Neurons - drug effects</topic><topic>Motor Neurons - metabolism</topic><topic>Nervous System Diseases - chemically induced</topic><topic>Nervous System Diseases - drug therapy</topic><topic>Neuropathy (peripheral)</topic><topic>Neuropharmacology</topic><topic>Peptide Fragments - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Postural Balance - drug effects</topic><topic>Psychomotor Performance - drug effects</topic><topic>Rats</topic><topic>Rats, Inbred Strains</topic><topic>Synaptic Transmission - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sporel-Özakat, R.Emine</creatorcontrib><creatorcontrib>Edwards, Philippa M.</creatorcontrib><creatorcontrib>Van der Hoop, Roland Gerritsen</creatorcontrib><creatorcontrib>Gispen, Willem H.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sporel-Özakat, R.Emine</au><au>Edwards, Philippa M.</au><au>Van der Hoop, Roland Gerritsen</au><au>Gispen, Willem H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An ACTH-(4–9) analogue, Org 2766, improves recovery from acrylamide neuropathy in rats</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>1990-09-21</date><risdate>1990</risdate><volume>186</volume><issue>2</issue><spage>181</spage><epage>187</epage><pages>181-187</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>Org 2766 is one of a series of melanocortis (ACTH and related peptides) that exert trophic influences on the central and peripheral nervous system of the rat. We used acrylamide neuropathy in rats as an experimental model of peripheral neuropathies of the dying-back type in order to assess the potential therapeutic efficacy of Org 2766 in this type of nerve damage. The peptide reversed the delayed persistent deficit in sensory conduction velocity without preventing the initial loss of motor coordination. The recovery of apparently normal coordination was unaffected by the peptide, but resistance to a second toxic challenge suggested that recovery was more complete in the peptide-treated rats. The finding that Org 2766 improved the quality of the repair following acrylamide neuropathy, together with previous studies showing beneficial effects in neuropathies caused by cisplatin or diabetes and after mechanical trauma, strongly suggests that Org 2766 may be beneficial in the treatment of various conditions in which the nervous system has sustained damage.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>1963145</pmid><doi>10.1016/0014-2999(90)90432-6</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-2999 |
| ispartof | European journal of pharmacology, 1990-09, Vol.186 (2), p.181-187 |
| issn | 0014-2999 1879-0712 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_15870610 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Acrylamide Acrylamides Adrenocorticotropic Hormone - analogs & derivatives Adrenocorticotropic Hormone - therapeutic use Animals Anticonvulsants - therapeutic use Biological and medical sciences Electrophysiology Female Medical sciences Melanocortins Miscellaneous Motor Neurons - drug effects Motor Neurons - metabolism Nervous System Diseases - chemically induced Nervous System Diseases - drug therapy Neuropathy (peripheral) Neuropharmacology Peptide Fragments - therapeutic use Pharmacology. Drug treatments Postural Balance - drug effects Psychomotor Performance - drug effects Rats Rats, Inbred Strains Synaptic Transmission - drug effects |
| title | An ACTH-(4–9) analogue, Org 2766, improves recovery from acrylamide neuropathy in rats |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T22%3A44%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20ACTH-(4%E2%80%939)%20analogue,%20Org%202766,%20improves%20recovery%20from%20acrylamide%20neuropathy%20in%20rats&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Sporel-%C3%96zakat,%20R.Emine&rft.date=1990-09-21&rft.volume=186&rft.issue=2&rft.spage=181&rft.epage=187&rft.pages=181-187&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/0014-2999(90)90432-6&rft_dat=%3Cproquest_cross%3E15870610%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15870610&rft_id=info:pmid/1963145&rft_els_id=0014299990904326&rfr_iscdi=true |